{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:55:24Z","timestamp":1785840924762,"version":"3.56.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT) is a well-established treatment in several hematological malignancies, where post-transplant complications are largely immune-driven. Post-transplantation (post-HCT) immune status assessment is essential for clinical monitoring of patients. In this study, immune cell composition and function was evaluated in whole blood from 77 adult allo-HCT recipients taken day +28 post-transplantation. High-resolution immunophenotyping assessed innate and adaptive immune compartments, including activation and immune checkpoint markers, while cytokine release after stimulation with T cell or innate stimuli examined immune function. Improved survival was associated with increased immune cell counts of both innate and adaptive immune compartments, as well as elevated cytokine-release responses. Elevated myeloid and innate lymphoid subsets and innately stimulated cytokine release were also associated with lower relapse incidence. Increased CD4 T cell PD-1 expression and HLA-DR on CD8 T cells was associated with poorer overall survival. These findings emphasize the importance of early innate immune reconstitution, indicating that integrating functional and phenotypic profiling could reveal new information regarding cell subsets of interest for allo-HCT patient monitoring, as well as potential targets for immunomodulation or cell therapies.<\/jats:p>","DOI":"10.1038\/s41409-026-02901-5","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T19:14:14Z","timestamp":1780168454000},"page":"1006-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-1475","authenticated-orcid":false,"given":"Patrick Terrence","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Minculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-0419","authenticated-orcid":false,"given":"Hans Jakob","family":"Hartling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Svanberg","family":"Teglgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Salado-Jimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Smidstrup","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kornblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Schj\u00f8dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Lykke","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Smedegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-7850","authenticated-orcid":false,"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Dam","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-9955","authenticated-orcid":false,"given":"Lars Klingen","family":"Gj\u00e6rde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-6522","authenticated-orcid":false,"given":"Hanne Vibeke","family":"Marquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5288-3851","authenticated-orcid":false,"given":"Sisse Rye","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"2901_CR1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, S\u00e1nchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217\u201339.","journal-title":"Bone Marrow Transpl"},{"key":"2901_CR2","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","volume":"26","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the american society for transplantation and cellular therapy. Biol Blood Marrow Transpl. 2020;26:1247\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2901_CR3","first-page":"642","volume":"27","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transpl Cell Ther. 2021;27:642\u20139.","journal-title":"Transpl Cell Ther"},{"key":"2901_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01217","volume":"9","author":"C Sweeney","year":"2019","unstructured":"Sweeney C, Vyas P. The graft-versus-leukemia effect in AML. Front Oncol. 2019;9:1\u201319.","journal-title":"Front Oncol"},{"key":"2901_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/17474086.2023.2273847","volume":"16","author":"K Maurer","year":"2023","unstructured":"Maurer K, Soiffer RJ. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2023;16:943\u201362.","journal-title":"Expert Rev Hematol"},{"key":"2901_CR6","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1182\/bloodadvances.2022008032","volume":"6","author":"S Nishiwaki","year":"2022","unstructured":"Nishiwaki S, Akahoshi Y, Morita-Fujita M, Shimizu H, Uchida N, Ozawa Y, et al. Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. Blood Adv. 2022;6:4558\u201369.","journal-title":"Blood Adv"},{"key":"2901_CR7","first-page":"768.e1","volume":"29","author":"M Ohbiki","year":"2023","unstructured":"Ohbiki M, Ito Y, Inamoto Y, Miyamura K, Uchida N, Fukuda T, et al. Improved long-term net survival after allogeneic hematopoietic cell transplantation in patients with hematologic malignancies over two decades. Transpl Cell Ther. 2023;29:768.e1\u2013768.e10.","journal-title":"Transpl Cell Ther"},{"key":"2901_CR8","first-page":"172.e1","volume":"31","author":"M Shahzad","year":"2025","unstructured":"Shahzad M, Iqbal Q, Amin MK, Kasaiean A, Oskouie IM, Warraich SZ, et al. Outcomes of allogeneic hematopoietic stem cell transplantation in patients aged 70 years and older: a systematic review and meta-analysis. Transpl Cell Ther. 2025;31:172.e1\u2013172.e13.","journal-title":"Transpl Cell Ther"},{"key":"2901_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood.2019000952","volume":"136","author":"GR Hill","year":"2020","unstructured":"Hill GR, Koyama M. Cytokines and costimulation in acute graft-versus-host disease. Blood. 2020;136:418\u201328.","journal-title":"Blood"},{"key":"2901_CR10","doi-asserted-by":"publisher","unstructured":"Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A et al. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation. Nat Commun. 2023; 14. https:\/\/doi.org\/10.1038\/s41467-023-38113-4.","DOI":"10.1038\/s41467-023-38113-4"},{"key":"2901_CR11","doi-asserted-by":"crossref","unstructured":"Boelens JJ, Hosszu KK, Nierkens S. Immune monitoring after allogeneic hematopoietic cell transplantation: toward practical guidelines and standardization. Front Pediatr. 2020;8:454.","DOI":"10.3389\/fped.2020.00454"},{"key":"2901_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/17843286.2020.1754635","volume":"76","author":"A Delie","year":"2021","unstructured":"Delie A, Verlinden A, Beel K, Deeren D, Mazure D, Baron F, et al. Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. Acta Clin Belgica: Int J Clin Lab Med. 2021;76:500\u20138.","journal-title":"Acta Clin Belgica: Int J Clin Lab Med"},{"key":"2901_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.00673","volume":"11","author":"D Adom","year":"2020","unstructured":"Adom D, Rowan C, Adeniyan T, Yang J, Paczesny S. Biomarkers for allogeneic HCT outcomes. Front Immunol. 2020;11:1\u201313.","journal-title":"Front Immunol"},{"key":"2901_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14728222.2021.1992383","volume":"25","author":"H Choe","year":"2021","unstructured":"Choe H, Ferrara JLM. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opin Ther Targets. 2021;25:761\u201371.","journal-title":"Expert Opin Ther Targets"},{"key":"2901_CR15","doi-asserted-by":"crossref","unstructured":"Chen S, Zeiser R. Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:1854.","DOI":"10.3389\/fimmu.2020.01854"},{"key":"2901_CR16","doi-asserted-by":"publisher","unstructured":"Pasin C, Moy RH, Reshef R, Yates AJ Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation. Sci Rep. 2021; 11. https:\/\/doi.org\/10.1038\/s41598-021-82562-0.","DOI":"10.1038\/s41598-021-82562-0"},{"key":"2901_CR17","doi-asserted-by":"crossref","unstructured":"Minculescu L, Marquart HV, Ryder LP, Andersen NS, Schjoedt I, Friis LS et al. Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. Front Immunol. 2019;10:1997.","DOI":"10.3389\/fimmu.2019.01997"},{"key":"2901_CR18","first-page":"94.e1","volume":"29","author":"W Mouton","year":"2023","unstructured":"Mouton W, Conrad A, Alcazer V, Boccard M, Bodinier M, Oriol G, et al. Distinct immune reconstitution profiles captured by immune functional assays at 6 months post allogeneic hematopoietic stem cell transplantation. Transpl Cell Ther. 2023;29:94.e1\u201394.e13.","journal-title":"Transpl Cell Ther"},{"key":"2901_CR19","first-page":"367","volume":"31","author":"W Mouton","year":"2025","unstructured":"Mouton W, Aguilhon L, Alcazer V, Carrer M, Franc P, Dupre C, et al. Temporal evolution of functional immune reconstitution after allogeneic HSCT. Transpl Cell Ther. 2025;31:367\u201381.","journal-title":"Transpl Cell Ther"},{"key":"2901_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/sji.13042","volume":"94","author":"LK Gj\u00e6rde","year":"2021","unstructured":"Gj\u00e6rde LK, Brooks PT, Andersen NS, Friis LS, Kornblit B, Petersen SL, et al. Functional immune reconstitution early after allogeneic haematopoietic cell transplantation: a comparison of pre- and post-transplantation cytokine responses in stimulated whole blood. Scand J Immunol. 2021;94:1\u201311.","journal-title":"Scand J Immunol"},{"key":"2901_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-06718-y","volume":"15","author":"PT Brooks","year":"2025","unstructured":"Brooks PT, Minculescu L, Svanberg Teglgaard R, Hartling HJ, Salado-Jimena JA, Friis LS, et al. Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients. Sci Rep. 2025;15:1\u201315.","journal-title":"Sci Rep"},{"key":"2901_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-022-00178-5","volume":"2","author":"R Svanberg","year":"2022","unstructured":"Svanberg R, MacPherson C, Zucco A, Agius R, Faitova T, Andersen MA, et al. Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients. Commun Med. 2022;2:1\u201315.","journal-title":"Commun Med"},{"key":"2901_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1097\/01.LAB.0000087589.37269.FC","volume":"83","author":"F Ethuin","year":"2003","unstructured":"Ethuin F, Delarche C, Gougerot-Pocidalo MA, Eurin B, Jacob L, Chollet-Martin S. Regulation of interleukin 12 p40 and p70 production by blood and alveolar phagocytes during severe sepsis. Lab Investig. 2003;83:1353\u201360.","journal-title":"Lab Investig"},{"key":"2901_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cca.2020.10.034","volume":"512","author":"L Pettersson","year":"2021","unstructured":"Pettersson L, Vezzi F, Vonlanthen S, Alwegren K, Hedrum A, Hauzenberger D. Development and performance of a next generation sequencing (NGS) assay for monitoring of mixed chimerism. Clin Chim Acta. 2021;512:40\u201348.","journal-title":"Clin Chim Acta"},{"key":"2901_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate : A practical and powerful approach to multiple testing author (s): Yoav Benjamini and Yosef Hochberg Source : Journal of the Royal Statistical Society. Series B (Methodological), Publi. J R Stat Soc. 1995;57:289\u2013300.","journal-title":"J R Stat Soc"},{"key":"2901_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41581-022-00633-5","volume":"19","author":"J Ochando","year":"2023","unstructured":"Ochando J, Mulder WJM, Madsen JC, Netea MG, Duivenvoorden R. Trained immunity \u2014 basic concepts and contributions to immunopathology. Nat Rev Nephrol. 2023;19:23\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"2901_CR27","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/TP.0000000000003673","volume":"105","author":"KT Cunningham","year":"2021","unstructured":"Cunningham KT, Mills KHG. Trained innate immunity in hematopoietic stem cell and solid organ transplantation. Transplantation. 2021;105:1666\u201376.","journal-title":"Transplantation"},{"key":"2901_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.bbmt.2018.10.013","volume":"25","author":"C de Koning","year":"2019","unstructured":"de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, et al. Innate immune recovery predicts CD4 + T cell reconstitution after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2019;25:819\u201326.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2901_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00507","volume":"7","author":"J Ogonek","year":"2016","unstructured":"Ogonek J, Juric MK, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:1\u201315.","journal-title":"Front Immunol"},{"key":"2901_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41568-023-00562-w","volume":"23","author":"B Ruf","year":"2023","unstructured":"Ruf B, Greten TF, Korangy F. Innate lymphoid cells and innate-like T cells in cancer \u2014 at the crossroads of innate and adaptive immunity. Nat Rev Cancer. 2023;23:351\u201371.","journal-title":"Nat Rev Cancer"},{"key":"2901_CR31","doi-asserted-by":"crossref","unstructured":"Hu Y, Hu Q, Li Y, Lu L, Xiang Z, Yin Z et al. \u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy. Signal Transduct Target Ther. 2023;8:434.","DOI":"10.1038\/s41392-023-01653-8"},{"key":"2901_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado S, Blanco-Dom\u00ednguez R, Silva-Santos B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat Rev Clin Oncol. 2023;20:178\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"2901_CR33","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00018-011-0699-1","volume":"68","author":"D Wesch","year":"2011","unstructured":"Wesch D, Peters C, Oberg HH, Pietschmann K, Kabelitz D. Modulation of \u03b3\u03b4 T cell responses by TLR ligands. Cell Mol Life Sci. 2011;68:2357\u201370.","journal-title":"Cell Mol Life Sci"},{"key":"2901_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071974","volume":"12","author":"L Dekker","year":"2020","unstructured":"Dekker L, de Koning C, Lindemans C, Nierkens S. Reconstitution of t cell subsets following allogeneic hematopoietic cell transplantation. Cancers (Basel). 2020;12:1\u201321.","journal-title":"Cancers (Basel)"},{"key":"2901_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2021.786017","volume":"9","author":"A Yanir","year":"2022","unstructured":"Yanir A, Schulz A, Lawitschka A, Nierkens S, Eyrich M. Immune reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions. Front Pediatr. 2022;9:1\u201325.","journal-title":"Front Pediatr"},{"key":"2901_CR36","doi-asserted-by":"publisher","unstructured":"Biernacki MA, Sheth VS, Bleakley M T cell optimization for graft-versusleukemia responses. JCI Insight. 2020; 5. https:\/\/doi.org\/10.1172\/jci.insight.134939.","DOI":"10.1172\/jci.insight.134939"},{"key":"2901_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbmt.2019.01.003","volume":"25","author":"LM Turcotte","year":"2019","unstructured":"Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, et al. Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. Biol Blood Marrow Transpl. 2019;25:883\u201390.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2901_CR38","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbmt.2011.08.007","volume":"18","author":"MD Thoma","year":"2012","unstructured":"Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, et al. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transpl. 2012;18:600\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2901_CR39","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/bmt.2012.211","volume":"48","author":"LJ Decook","year":"2013","unstructured":"Decook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA, Patnaik MM, et al. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. Bone Marrow Transpl. 2013;48:708\u201314.","journal-title":"Bone Marrow Transpl"},{"key":"2901_CR40","first-page":"139","volume":"176","author":"B Dhakal","year":"2019","unstructured":"Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A. Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. Physiol Behav. 2019;176:139\u201348.","journal-title":"Physiol Behav"},{"key":"2901_CR41","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.bbmt.2016.04.015","volume":"22","author":"A Le Bourgeois","year":"2016","unstructured":"Le Bourgeois A, Peterlin P, Guillaume T, Delaunay J, Duquesne A, Le Gouill S, et al. Higher early monocyte and total lymphocyte counts are associated with better overall survival after standard total body irradiation, cyclophosphamide, and fludarabine reduced-intensity conditioning double umbilical cord blood allogeneic stem cell transpla. Biol Blood Marrow Transpl. 2016;22:1473\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2901_CR42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/jha2.795","volume":"4","author":"P Peterlin","year":"2023","unstructured":"Peterlin P, B\u00e9n\u00e9 MC, Jullien M, Guillaume T, Bourgeois AL, Garnier A, et al. Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients. EJHaem. 2023;4:1089\u201395.","journal-title":"EJHaem"},{"key":"2901_CR43","doi-asserted-by":"crossref","unstructured":"Demosthenous C, Sakellari I, Douka V, Papayanni PG, Anagnostopoulos A, Gavriilaki E. The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD). J Clin Med. 2021;10:2050.","DOI":"10.3390\/jcm10102050"},{"key":"2901_CR44","doi-asserted-by":"publisher","unstructured":"Park MJ, Baek JA, Kim SY, Jung KA, Choi JW, Park SH et al. Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells. J Transl Med. 2020; 18. https:\/\/doi.org\/10.1186\/s12967-020-02657-6.","DOI":"10.1186\/s12967-020-02657-6"},{"key":"2901_CR45","doi-asserted-by":"crossref","unstructured":"Ma L, Koehn B, Zaiken M, Hippen KL, Smith K, Allred J et al. Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease. 2025;146:2047\u201362.","DOI":"10.1182\/blood.2025028562"},{"key":"2901_CR46","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1182\/blood-2011-11-364091","volume":"119","author":"EO Stenger","year":"2012","unstructured":"Stenger EO, Turnquist HR, Mapara MY, Thomson AW. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood. 2012;119:5088\u2013103.","journal-title":"Blood"},{"key":"2901_CR47","doi-asserted-by":"crossref","unstructured":"Toubai T, Mathewson N, Reddy P. The role of dendritic cells in graft-versus-tumor effect. Front Immunol. 2014;5:66.","DOI":"10.3389\/fimmu.2014.00066"},{"key":"2901_CR48","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432\u201347.","journal-title":"Cell Mol Immunol"},{"key":"2901_CR49","doi-asserted-by":"publisher","unstructured":"Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun. 2019; 10. https:\/\/doi.org\/10.1038\/s41467-019-08871-1.","DOI":"10.1038\/s41467-019-08871-1"},{"key":"2901_CR50","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1182\/blood.2022015522","volume":"140","author":"V Gournay","year":"2022","unstructured":"Gournay V, Vallet N, Peux V, Vera K, Bordenave J, Lambert M, et al. Immune landscape after allo-HSCT: TIGIT-and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. Blood. 2022;140:1305\u201321.","journal-title":"Blood"},{"key":"2901_CR51","doi-asserted-by":"crossref","unstructured":"Cui H, Hamad M, Elkord E TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies. Cell Death Dis. 2025;16:664.","DOI":"10.1038\/s41419-025-07984-4"},{"key":"2901_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","volume":"130","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: High response rate but frequent GVHD. Blood. 2017;130:221\u20138.","journal-title":"Blood"},{"key":"2901_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40164-025-00697-6","volume":"14","author":"TTD Pham","year":"2025","unstructured":"Pham TTD, Choi SY, Koh JS, Heo BY, Lee SW, Lee MW, et al. Elevated TIM3 expression on bone marrow T cells drives immune dysfunction in early relapsed blood cancer after allogeneic hematopoietic stem cell transplantation. Exp Hematol Oncol. 2025;14:107.","journal-title":"Exp Hematol Oncol"},{"key":"2901_CR54","first-page":"357.e1","volume":"31","author":"J Kuruvilla","year":"2025","unstructured":"Kuruvilla J, Armand P, Herrera AF, Ribrag V, Thieblemont C, von Tresckow B, et al. Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab Therapy. Transpl Cell Ther. 2025;31:357.e1\u2013357.e11.","journal-title":"Transpl Cell Ther"},{"key":"2901_CR55","doi-asserted-by":"crossref","unstructured":"Kaphan E, Bettega F, Vallet N, Fegueux N, Robin M, Bazarbachi A et al. PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Haematologica. 2024; 3373-8.","DOI":"10.3324\/haematol.2024.284968"},{"key":"2901_CR56","doi-asserted-by":"publisher","unstructured":"Laurie SJ, Foster JP, Bruce DW, Bommiasamy H, Kolupaev OV, Yazdimamaghani M et al. Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Commun. 2024; 15. https:\/\/doi.org\/10.1038\/s41467-024-50263-7.","DOI":"10.1038\/s41467-024-50263-7"},{"key":"2901_CR57","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-018-0001-y","volume":"18","author":"T Van Den Broek","year":"2018","unstructured":"Van Den Broek T, Borghans JAM, Van Wijk F. The full spectrum of human naive T cells. Nat Rev Immunol. 2018;18:363\u201373.","journal-title":"Nat Rev Immunol"},{"key":"2901_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/anae.16161","volume":"79","author":"D Sidebotham","year":"2024","unstructured":"Sidebotham D, Barlow CJ. The winner\u2019s curse: why large effect sizes in discovery trials always get smaller and often disappear completely. Anaesthesia. 2024;79:86\u201390.","journal-title":"Anaesthesia"},{"key":"2901_CR59","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/1744666X.2025.2450014","volume":"21","author":"H Reikvam","year":"2025","unstructured":"Reikvam H, Tsykunova G, Sandnes M, Wendelbo \u00d8. Infectious complications and the utility of serum and cellular markers of infections in the setting of allogeneic hematopoietic stem cell transplantation. Expert Rev Clin Immunol. 2025;21:291\u2013303.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02901-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02901-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02901-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:36:34Z","timestamp":1785839794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02901-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2901"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02901-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}